In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, outlines the key ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, discusses how real-time data access is helping biotechs accelerate trial timelines, ensure ...

Since the Russian invasion in February 2022, Ukraine’s healthcare system has endured unprecedented strain, including in clinical trials.

Men with prostate cancer could get access to life-saving trials within hours, under a programme to speed up access to ...

The number of cancer clinical trial participants at the hospital as of July was down about 20% from last year, one NIH cancer ...

Cuts to the NIH hurting the scientific community at large, but cuts to the NIH hurt our families and friends in our home ...

The Allan Labor Government has welcomed a new BioNTech clinical trial platform that will provide cancer patients with easier access to the next ...

The U.S. FDA granted accelerated approval to Modeyso for the patients with diffuse midline glioma with an H3 K27M mutation ...

Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head-to-head trials.

Key Points Surrozen reported GAAP EPS of $2.55 for Q2 2025, exceeding expectations by $3.66 per share (GAAP) due to significant one-time and non-cash gains. Surrozen recorded $1.0 million in research ...

Victoria is cementing its position as a global hub for biotechnology and life sciences, with BioNTech establishing a state-of ...

Adolescents and young adults with cancer who are navigating life between childhood and early adulthood face a unique set of ...